E-viri
-
Zhang, X S; Liu, B C; Du, X; Zhang, Y L; Xu, N; Liu, X L; Li, W M; Lin, H; Liang, R; Chen, C Y; Huang, J; Yang, Y F; Zhu, H L; Pan, L; Wang, X D; Li, G H; Liu, Z G; Zhang, Y Q; Liu, Z F; Hu, J D; Liu, C S; Li, F; Yang, W; Meng, L; Han, Y Q; Lin, L E; Zhao, Z Y; Tu, C Q; Zheng, C F; Bai, Y L; Zhou, Z P; Chen, S N; Qiu, H Y; Yang, L J; Sun, X L; Sun, H; Zhou, L; Liu, Z L; Wang, D Y; Guo, J X; Pang, L P; Zeng, Q S; Suo, X H; Zhang, W H; Zheng, Y J; Jiang, Q
Zhōnghuá xuèyèxué zázhì, 09/2023, Letnik: 44, Številka: 9Journal Article
Objective: To analyze and compare therapy responses, outcomes, and incidence of severe hematologic adverse events of flumatinib and imatinib in patients newly diagnosed with chronic phase chronic myeloid leukemia (CML) . Methods: Data of patients with chronic phase CML diagnosed between January 2006 and November 2022 from 76 centers, aged ≥18 years, and received initial flumatinib or imatinib therapy within 6 months after diagnosis in China were retrospectively interrogated. Propensity score matching (PSM) analysis was performed to reduce the bias of the initial TKI selection, and the therapy responses and outcomes of patients receiving initial flumatinib or imatinib therapy were compared. Results: A total of 4 833 adult patients with CML receiving initial imatinib (n=4 380) or flumatinib (n=453) therapy were included in the study. In the imatinib cohort, the median follow-up time was 54 interquartile range (IQR), 31-85 months, and the 7-year cumulative incidences of CCyR, MMR, MR(4), and MR(4.5) were 95.2%
